BIRC5 and cancer: Nevertheless, while survivin expression is inhibited by wild type p53 [27-29], survivin and NF-κB appear to be co-expressed in cancer such as in peripheral T-cell lymphoma [45], and inhibition of NF-κB activity using NF-κB-specific inhibitors decreased survivin expression [46].